Form 8-K - Current report:
SEC Accession No. 0001193125-25-044151
Filing Date
2025-03-03
Accepted
2025-03-03 16:30:48
Documents
13
Period of Report
2025-03-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d940925d8k.htm   iXBRL 8-K 23390
  Complete submission text file 0001193125-25-044151.txt   144761

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250303.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250303_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250303_pre.xml EX-101.PRE 11262
15 EXTRACTED XBRL INSTANCE DOCUMENT d940925d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 25698495
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)